Abstract 4553: The CD25 antibody RG6292 selectively depletes Tregs while preserving IL-2 signaling and CTL activity for tumor control | Citedby Results | Cancer Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Abstract 4553: The CD25 antibody RG6292 selectively depletes Tregs while preserving IL-2 signaling and CTL activity for tumor control

Cancer Res (2020) 80 (16_Supplement): 4553.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia

Laurène Pousse
Koorosh Korfi
Bruno C. Medeiros
Marco Berrera
Nadine Kumpesa
Jan Eckmann
Idil Karakoc Hutter
Vera Griesser
Vaios Karanikas
Christian Klein
Maria Amann

Frontiers in Oncology (2023) 13

Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment

Bayley R. McRitchie
Billur Akkaya

Frontiers in Immunology (2022) 13

Therapeutic Targeting of Tumor-Infiltrating Regulatory T Cells in Breast Cancer

Stephane Fattori
Hugo Roux
Emilie Connen
Lucie Robert
Laurent Gorvel
Aude Le Roy
Jemila Houacine
Arnaud Foussat
Anne-Sophie Chretien
Daniel Olive

Cancer Research (2022) 82 (21): 3868.

The Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities

Fatemeh Bayati
Mahsa Mohammadi
Maryam Valadi
Saeid Jamshidi
Arron Munggela Foma
Ehsan Sharif-Paghaleh

Frontiers in Immunology (2021) 11